Focus on Anticoagulation Care

Back to articles

New oral option for cancer-associated VTE

April 10, 2018
  • Advising on this article:
  • Sarah Ray

KEY POINT

Use of long-term oral edoxaban (Savaysa—Daiichi-Sankyo) in patients with cancer and an acute venous thromboembolism (VTE) was found to be noninferior to long-term use of subcutaneous dalteparin for recurrent VTE or major bleeding, according to results of the Hokusai VTE Cancer trial published in the New England Journal of Medicine.

SOURCES

Raskob GE, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–24.

Hirsh J, et al. Edoxaban for the treatment of venous thromboembolism in patients with cancer. N Engl J Med. 2018;378(7):673–4. 

Recent Articles

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

More info

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.